We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Merck (MRK - Free Report) closed at $75.91 in the latest trading session, marking a +0.82% move from the prior day. This change outpaced the S&P 500's 0.87% loss on the day. Elsewhere, the Dow lost 0.08%, while the tech-heavy Nasdaq lost 0.43%.
Coming into today, shares of the pharmaceutical company had lost 8.85% in the past month. In that same time, the Medical sector lost 0.67%, while the S&P 500 gained 0.7%.
Investors will be hoping for strength from Merck as it approaches its next earnings release. The company is expected to report EPS of $1.45, up 9.85% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $12.62 billion, up 0.84% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $5.77 per share and revenue of $48.88 billion, which would represent changes of -2.86% and +1.85%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Merck. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.64% higher. Merck is currently a Zacks Rank #3 (Hold).
Digging into valuation, Merck currently has a Forward P/E ratio of 13.05. This represents a discount compared to its industry's average Forward P/E of 13.55.
It is also worth noting that MRK currently has a PEG ratio of 1.97. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.07 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 94, putting it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MRK in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Merck (MRK) Gains As Market Dips: What You Should Know
Merck (MRK - Free Report) closed at $75.91 in the latest trading session, marking a +0.82% move from the prior day. This change outpaced the S&P 500's 0.87% loss on the day. Elsewhere, the Dow lost 0.08%, while the tech-heavy Nasdaq lost 0.43%.
Coming into today, shares of the pharmaceutical company had lost 8.85% in the past month. In that same time, the Medical sector lost 0.67%, while the S&P 500 gained 0.7%.
Investors will be hoping for strength from Merck as it approaches its next earnings release. The company is expected to report EPS of $1.45, up 9.85% from the prior-year quarter. Meanwhile, our latest consensus estimate is calling for revenue of $12.62 billion, up 0.84% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $5.77 per share and revenue of $48.88 billion, which would represent changes of -2.86% and +1.85%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for Merck. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.64% higher. Merck is currently a Zacks Rank #3 (Hold).
Digging into valuation, Merck currently has a Forward P/E ratio of 13.05. This represents a discount compared to its industry's average Forward P/E of 13.55.
It is also worth noting that MRK currently has a PEG ratio of 1.97. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 2.07 based on yesterday's closing prices.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 94, putting it in the top 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MRK in the coming trading sessions, be sure to utilize Zacks.com.